• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IHL 0.00% 4.1¢

INCANNEX HEALTHCARE LIMITED - News & Media

Incannex Healthcare Limited is an Australia-based clinical-stage pharmaceutical... Incannex Healthcare Limited is an Australia-based clinical-stage pharmaceutical development company. The Company is focused on developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of generalized anxiety disorder (GAD), obstructive sleep apnea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation, rheumatoid arthritis and inflammatory bowel disease. Its drug candidates include IHL-42X, IHL-216A and HL-675A. Its IHL-42X is a combination of acetazolamide and dronabinol for treatment of OSA. Its IHL-216A is a combination of isoflurane and cannabidiol (CBD) to prevent development of TBI/concussion. Its HL-675A comprises a combination of hydroxychloroquine and CBD for prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel diseases. It is also investigating the use of psilocybin assisted psychotherapy to treat GAD.More

No News & Media currently available.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.